Harnessing single-domain antibodies for CAR-T and bispecific antibody development [0.03%]
单结构域抗体在CAR-T和双特异性抗体开发中的应用
Mooyoung Jung,Jeong Yeon Hwang,Hyunbo Shim
Mooyoung Jung
Emerging antibody-based therapeutic modalities such as CAR-Ts and bispecific antibodies have proven highly efficacious in treating diseases, including hematological malignancies. However, the complex molecular architectures of these novel a...
Frederik Damm,Lars Bullinger
Frederik Damm
Tailoring intensive and less-intensive treatment in acute myeloid leukemia [0.03%]
急性髓系白血病的强化及减强度治疗策略定制化思考
Carolin Seeling,Arnold Ganser,Hartmut Döhner et al.
Carolin Seeling et al.
After decades of therapeutic inertia, the treatment of acute myeloid leukemia (AML) has seen remarkable improvements over the past ten years. Scientific discoveries have substantially enhanced the understanding of AML disease biology. The i...
Himachandana Atluri,Alok Swaroop,Lucy A Godley
Himachandana Atluri
Germline predisposition syndromes to myeloid malignancies have been recognized increasingly over the last decade. Although many of these genetic syndromes present early in life, the age at which a hematopoietic malignancy develops can vary ...
The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies [0.03%]
急性髓系白血病免疫疗法现状：定义知识空白以实现理性联合策略
Marion Subklewe,Sergio Rutella,Antonio Curti
Marion Subklewe
Immunotherapy has dramatically improved outcomes in lymphoid malignancies. In B cell cancers, CD19-directed CAR T cells and T-cell engagers have produced high remission rates and durable responses, now forming the cornerstone of treatment i...
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers [0.03%]
临床可用的双特异性T细胞衔接器中抗CD3抗体的特征分析
Hyeonmin Lee,Yonghee Lee,Junho Chung
Hyeonmin Lee
Bispecific T cell engagers (bispecific TCEs) are engineered antibodies that redirect T cells to mediate tumor cell killing by simultaneously binding to CD3 on T cells and tumor-associated antigens. As of July 2025, ten bispecific TCEs are c...
Daniela V Wenge,Scott A Armstrong
Daniela V Wenge
Menin inhibitors are emerging as targeted therapies for acute leukemias with high HOXA gene expression. These leukemias harbor mutations including KMT2A-rearrangements, NPM1c mutations, NUP98-fusions, UBTF tandem duplications and potentiall...
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics [0.03%]
单细胞多组学解析白血病干细胞的异质性和可塑性
Frank Y Huang,Andreas Trumpp,Patrick Stelmach
Frank Y Huang
Acute myeloid leukemia (AML) is an aggressive blood cancer in which disease initiation and relapse are driven by leukemic cells with stem-like properties, known as leukemic stem cells (LSCs). The LSC compartment is highly heterogenous and t...
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories [0.03%]
继发性和治疗相关性急性髓系白血病：重叠特征与不同轨迹
Luca Guarnera,Emiliano Fabiani,Giorgia Silvestrini et al.
Luca Guarnera et al.
Therapy-related acute myeloid leukemia (tAML) and AML arising from previous hematologic disorders (secondary AML, sAML) share similar biological features, including karyotype abnormalities and gene specific mutations, patient-related risk f...
Jens Schrezenmeier,B J P Huntly
Jens Schrezenmeier
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy defined by the clonal expansion of undifferentiated myeloid blasts with a block in differentiation and aberrant self-renewal. While recurrent genomic mutations are well-do...